BEVERLY HILLS, Calif., June 21, 2016 /PRNewswire/ -- Rich Pharmaceuticals, Inc. (OTCPK: RCHA) ("Rich" or the "Company"), announced today it has entered into an additional agreement with Theradex Systems, Inc. ("Theradex"), a leading global Contract Research Organization ("CRO"), to assist the Company in submitting a protocol to the US FDA for Hodgkin's Lymphoma under the company's existing Investigational New Drug Application (IND).
"We selected Theradex to assist the Company in pursuing our proposed studies in Hodgkin's Lymphoma because of Theradex's invaluable assistance in finalizing our prior IND with the FDA for Rich's lead drug RP-323 in patients with AML," said Ben Chang, CEO of Rich.
Hodgkin's lymphoma is a cancer that is found most frequently in two different age groups: 15 – 35 and over 55, and occurs in both sexes although it is more common in males and individuals with HIV. Malignant Reed Sternberg cells invade and destroy the architecture of the lymph nodes and infiltrate major organs such as the liver and spleen. Radiation and chemotherapy are used routinely but these treatments can later result in morbidity and mortality as a result of causing second malignancies. In the U.S., over 100,000 people suffer from Hodgkin's lymphoma.
About Theradex Systems, Inc.:
Theradex Systems, Inc. is an international contract research organization providing complete professional services for the clinical research and development of pharmaceutical compounds, medical devices and diagnostic tests in the areas of oncology and life-threatening diseases. Theradex conducts studies that lead to marketing approval of significant medical advances; and has built a reputation on assuring the scientific objectivity and meticulous quality control that fulfills all regulatory requirements. Theradex's expertise is also available to assist client personnel in expedited development planning and execution. Find out more at www.theradex.com
This press release contains certain "forward-looking statements" which are statements that are not purely historical, and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that they will prove to be accurate. Investors should refer to the risk factors disclosure outlined in the reports and other documents we file with the SEC (at www.sec.gov).
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/rich-pharmaceuticals-retains-theradex-systems-to-help-advance-its-hodgkins-lymphoma-indication-300287798.html
SOURCE Rich Pharmaceuticals, Inc.